cpuwy
Lv2
140 积分
2021-06-07 加入
-
Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
1个月前
已完结
-
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2个月前
已完结
-
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
3个月前
已完结
-
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
3个月前
已完结
-
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
3个月前
已完结
-
Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis
4个月前
已完结
-
Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections
6个月前
已关闭
-
Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections
6个月前
已关闭
-
Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids
9个月前
已关闭
-
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss
10个月前
已完结